Keros Therapeutics Announces First Patient Dosed in Phase 2 DMD Trial

What Happened

• On September 28, 2026, Keros Therapeutics, Inc. announced by press release (furnished on a Form 8‑K under Item 7.01) that the first patient has been dosed in its Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy (DMD). The press release was furnished as an exhibit to the Form 8‑K.

Key Details

• Event: First patient dosed in Phase 2 trial of rinvatercept for DMD.
• Filing date: Press release dated and furnished on September 28, 2026 (Form 8‑K, Item 7.01).
• Disclosure status: Information was furnished under Regulation FD and is expressly noted as furnished (not “filed”) for Section 18 purposes.
• Exhibit: Press release furnished as Exhibit 99.1 to the Current Report.

Why It Matters

• Dosing the first patient is a key operational milestone confirming the Phase 2 study has started enrollment and dosing. This is an important clinical-development update for investors tracking Keros’s pipeline progress. The filing does not include trial results or financial guidance; investors should look for subsequent company disclosures for enrollment progress, safety/efficacy readouts, and any associated timelines.